Impact of positive CD4 cells on event-free survival in follicular lymphoma patients

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-09-09 DOI:10.1002/cam4.70117

Cong Li, Na Guo, Shuiyun Han, Haifeng Yu, Tao Lei, Xi Chen, Shuailing Peng, Haiyan Yang, Meijuan Wu

{"title":"Impact of positive CD4 cells on event-free survival in follicular lymphoma patients","authors":"Cong Li, Na Guo, Shuiyun Han, Haifeng Yu, Tao Lei, Xi Chen, Shuailing Peng, Haiyan Yang, Meijuan Wu","doi":"10.1002/cam4.70117","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1-3A. Early failure was described as failing to achieve event-free survival (EFS) at 12 or 24 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with <20% of positive CD4 cells, patients with ≥20% of positive CD4 cells exhibited a significant lower risk of early failure (2-year EFS rate: 56.7% vs 73.5%, <i>p</i> = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (<i>p</i> = 0.002) and median OS (<i>p</i> = 0.007) were significantly different.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70117","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70117","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial.

Methods

Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1-3A. Early failure was described as failing to achieve event-free survival (EFS) at 12 or 24 months.

Results

There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with <20% of positive CD4 cells, patients with ≥20% of positive CD4 cells exhibited a significant lower risk of early failure (2-year EFS rate: 56.7% vs 73.5%, p = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (p = 0.002) and median OS (p = 0.007) were significantly different.

Conclusions

This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CD4 细胞阳性对滤泡淋巴瘤患者无事件生存期的影响。

目的以往关于滤泡性淋巴瘤（FL）中 CD4+ T 细胞预后价值的研究结果仍存在争议：方法：采用免疫组化方法检测103例FL 1-3A患者CD4阳性细胞的表达。结果：103例FL 1-3A患者中，有49例（47.6%）CD4细胞表达阳性：结果：103 名 FL 1-3A 患者中有 49 名男性（47.6%）和 54 名女性（52.4%），中位年龄为 54 岁。结果：男性 49 人（47.6%），女性 54 人（52.4%），中位年龄 54 岁：这项研究表明，CD4细胞阳性表达越高，预测滤泡性淋巴瘤早期失败的风险越低，CD4和FLIPI的联合分析能更好地预测疾病复发和生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.